OTSA101 is an anti-FZD10 antibody and has been developed as novel cancer therapy for synovial sarcoma. FZD10, which was identified through genome-wide analysis by the group of Professor Yusuke Nakamura (former Director of Human genome center, Institute of Medical Science,The University of Tokyo ) is frequently and highly upregulated in synovial sarcoma but being hardly detectable in normal organs.
OTSA101 specifically binds to FZD10 in cancer cells. Radioactive isotope-conjugated OTSA101 showed strong anti-cancer activity by tumor-specific irradiation in mouse xenograft model.
In addition, OTSA101 is designated as an orphan drug for treatment of soft tissue sarcoma by Food and Drug Administration (FDA) respectively.